One leading cause of aqueous-deficient dry eye disease (ADDE) in humans is Sjögren syndrome (SS).[@i1552-5783-60-6-2181-b01] This autoimmune disease occurs almost exclusively in women and is associated with an extensive inflammation in the lacrimal gland, immune-mediated destruction and/or dysfunction of glandular epithelial cells, and significant decrease in aqueous tear output.[@i1552-5783-60-6-2181-b01] This sexual dichotomy in SS prevalence has been linked to the more potent immune capability of women,[@i1552-5783-60-6-2181-b02][@i1552-5783-60-6-2181-b03]--[@i1552-5783-60-6-2181-b04] as well as to the differential action of sex steroids on the immune system.[@i1552-5783-60-6-2181-b05] Androgens often provide a protective influence and suppress various immunopathologies in SS and other autoimmune diseases. In contrast, estrogens have been implicated in the pathogenesis and/or progression of numerous autoimmune disorders, including SS.[@i1552-5783-60-6-2181-b02],[@i1552-5783-60-6-2181-b05][@i1552-5783-60-6-2181-b06]--[@i1552-5783-60-6-2181-b07]

Of particular interest, androgen deficiency appears to have an important role in the development of lacrimal gland inflammation and ADDE in SS. Correction of this hormonal deficit, in turn, may have a therapeutic benefit. To explain, androgens are very potent regulators of the lacrimal gland and their action seems to account for many of the sex-related differences that exist in the anatomy, biochemistry, physiology, immunology, and molecular biology of this tissue.[@i1552-5783-60-6-2181-b05] However, androgen levels in women with SS are significantly decreased.[@i1552-5783-60-6-2181-b08][@i1552-5783-60-6-2181-b09]--[@i1552-5783-60-6-2181-b10] We hypothesized that this reduction predisposes to lacrimal gland dysfunction, attenuated tear secretion, and ADDE. In support of our hypothesis, we discovered that testosterone administration to female mouse models of SS (e.g., MRL/MpJ-Tnfrsf6^lpr^ \[MRL/lpr\] and NZB/NZW F1) suppresses inflammation in, and increases the functional activity of, lacrimal tissue.[@i1552-5783-60-6-2181-b07],[@i1552-5783-60-6-2181-b11][@i1552-5783-60-6-2181-b12][@i1552-5783-60-6-2181-b13][@i1552-5783-60-6-2181-b14]--[@i1552-5783-60-6-2181-b15] Similarly, topical and/or systemic androgen treatment appears to completely resolve lacrimal gland inflammation in dry eye dogs,[@i1552-5783-60-6-2181-b16],[@i1552-5783-60-6-2181-b17] and to alleviate dry eye signs and symptoms and promote tear flow in SS patients.[@i1552-5783-60-6-2181-b05]

The mechanism(s) involved in this androgen-induced suppression of lacrimal gland autoimmune disease in SS remains to be clarified. Our evidence indicates that this hormone action is a unique, tissue-specific effect, which is initiated through androgen binding to specific receptors in lacrimal gland epithelial cells.[@i1552-5783-60-6-2181-b07] In addition, we hypothesize that this androgen interaction then elicits the altered expression and/or activity of immune-related genes in lacrimal tissue, leading to a decrease in immunopathologic lesions and an improvement in glandular function.

To begin to test this hypothesis, we examined the nature and magnitude of testosterone\'s influence on immune-related gene expression in the autoimmune lacrimal tissues of female MRL/lpr mice after onset of disease. We chose the MRL/lpr strain because, like in humans, the extent of lacrimal and salivary gland inflammation in MRL/lpr mice is far greater in females compared to males,[@i1552-5783-60-6-2181-b18] and is dramatically reduced in response to androgen treatment.[@i1552-5783-60-6-2181-b07],[@i1552-5783-60-6-2181-b11][@i1552-5783-60-6-2181-b12][@i1552-5783-60-6-2181-b13]--[@i1552-5783-60-6-2181-b14]

For comparative purposes, we also analyzed and compared the androgen impact on immune gene expression in lacrimal glands of female nonobese diabetic/LtJ (NOD) mice after onset of disease. These mice, which are an established model for type-1 insulin-dependent diabetes mellitus,[@i1552-5783-60-6-2181-b19] have been used as a model for Sjögren syndrome[@i1552-5783-60-6-2181-b20][@i1552-5783-60-6-2181-b21]--[@i1552-5783-60-6-2181-b22] and, like in humans, have far greater inflammation in the salivary glands of females compared to males.[@i1552-5783-60-6-2181-b18] However, unlike humans, the lacrimal glands of male NOD mice have significantly higher inflammation than those of females.[@i1552-5783-60-6-2181-b18],[@i1552-5783-60-6-2181-b23][@i1552-5783-60-6-2181-b24]--[@i1552-5783-60-6-2181-b25] Indeed, orchiectomy of NOD mice attenuates, whereas androgen treatment of castrated NOD males induces, lymphocyte accumulation in their lacrimal glands.[@i1552-5783-60-6-2181-b23] This anomalous hormone effect is mediated through the lacrimal microenvironment[@i1552-5783-60-6-2181-b24] and contrasts with the androgen-induced decrease in inflammation in salivary and pancreatic tissues in these mice.[@i1552-5783-60-6-2181-b26],[@i1552-5783-60-6-2181-b27] Given this background, we hypothesized that androgen exposure will significantly increase the expression and/or activity of immune-related genes in the lacrimal glands of female NOD mice. We also hypothesized that these opposing actions of androgens in female MRL/lpr and NOD lacrimal tissues involve regulation of similar immune-related genes, ontologies, and pathways.

Materials and Methods {#s2}
=====================

Animals and Tissue Collections {#s2a}
------------------------------

Adult female MRL/lpr and NOD mice were purchased from the Jackson Laboratories (Bar Harbor, ME, USA). Animals were maintained in constant temperature rooms with fixed light/dark intervals 12 hours in duration. Pellets containing vehicle (cholesterol, methylcellulose, lactose) or testosterone (T; 10 mg) were implanted subcutaneously in MRL/lpr (17.1--18.1 weeks old) and NOD (21 weeks old) mice. The pellets were obtained from Innovative Research of America (Sarasota, FL, USA) and were designed for constant release of placebo (P) or physiologic amounts of androgen (for a male[@i1552-5783-60-6-2181-b11][@i1552-5783-60-6-2181-b12][@i1552-5783-60-6-2181-b13]--[@i1552-5783-60-6-2181-b14]) for a 3-week period. After 20 to 21 days of treatment, mice (*n* = 7--18 mice/condition) were killed by CO~2~ inhalation and exorbital lacrimal glands were removed for molecular biological procedures. Lacrimal tissue samples were prepared by combining glands from two to six mice/strain/group. Three different sample preparations were made for each treatment (i.e., 4--12 lacrimal glands/sample/treatment/strain) and then processed for analysis of gene expression.

All mouse studies were approved by the institutional animal care and use committee of the Schepens Eye Research Institute and adhered to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.

Molecular Biological Procedures {#s2b}
-------------------------------

To determine the effect of T on lacrimal gland gene expression, total RNA was isolated from lacrimal tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and purified with RNAqueous spin columns (Ambion, Austin, TX, USA). Lacrimal gland RNA samples were treated with RNase-free DNase (Invitrogen), assessed spectrophotometrically at 260 nm to determine concentration, and examined with a RNA 6000 Nano LabChip and an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) to verify RNA integrity. The RNA samples were kept at −80°C until further processing.

Gene expression was determined via two different procedures. One involved hybridization of lacrimal gland RNA samples to CodeLink (CL) UniSet Mouse 20K I Bioarrays (*n* ∼ 20,000 genes/array; Amersham Biosciences/GE Healthcare, Piscataway, NJ, USA), according to reported methods.[@i1552-5783-60-6-2181-b28] cDNA was generated from RNA (2 μg) with a CL Expression Assay Reagent Kit (Amersham) and purified with a QIAquick purification kit (Qiagen, Valencia, CA, USA). Samples were dried, and cRNA was made with a CL Expression Assay Reagent Kit (Amersham), recovered with an RNeasy kit (Qiagen), and quantified with an ultraviolet spectrophotometer. Fragmented, biotin-labeled cRNA then was incubated and shaken at 300 rpm on a CL Bioarray at 37°C for 18 hours. Following this time interval, the Bioarray was washed, exposed to streptavidin-Alexa 647, and scanned using ScanArray Express software and a ScanArray Express HT scanner (Packard BioScience, Meriden, CT, USA) with the laser set at 635 nm, laser power at 100%, and photomultiplier tube voltage at 60%. Scanned image files were evaluated using CL image and data analysis software (Amersham), which gave raw and normalized hybridization signal intensities for each array spot. The intensities of the approximately 20,000 spots on the Bioarray image were normalized to a median of 1. Standardized data, with signal intensities \>0.50, were analyzed with bioinformatic software (Geospiza, Seattle, WA, USA). This comprehensive software also produced gene ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, and *z*-score reports. The ontologies included those related to biological processes, molecular functions, and cellular components, and were organized according to the recommended guidelines of the Gene Ontology Consortium (available in the public domain at <http://www.geneontology.org/GO.doc.html>).[@i1552-5783-60-6-2181-b29]

The second method to determine differential gene expression entailed hybridization of each cRNA (20 μg) sample to a GeneChip Mouse Genome 430A 2.0 Array (Affymetrix \[Affy\], Santa Clara, CA, USA) according to the manufacturer\'s protocol. Reagents for the fragmentation and hybridization steps originated from a GeneChip HT One-Cycle Target Labeling and Control Kit, and materials for the washing and staining steps were from a GeneChip HWS kit (Affy). Hybridized GeneChips were scanned with an Affy Model 700 Scanner and expression data files were generated from array images using Affy Microarray Suite 4.0 software. GeneChip data were normalized by choosing the default scaling in the Affy GeneChip operating software, which gives a trimmed mean intensity of 500 for each GeneChip microarray. Standardized data with a quality value of 1.0 then were evaluated with Geospiza GeneSifter software.

As we reported recently,[@i1552-5783-60-6-2181-b30] counts of unique mappings of probes to gene identifications in the CL and Affy arrays demonstrated that there were 15,711 and 13,265 unique genes, respectively, in these arrays. Examination of the intersection of these lists showed that there was an overlap of 11,299 genes.

Gene expression data were evaluated without log transformation and statistical analyses were conducted with Student\'s *t*-test (2-tailed, unpaired) using the GeneSifter software. Our statistical method was not tailored for multiple comparisons. Genes expressed in the same direction in comparative groups were identified using GenBank accession numbers and a Geospiza intersector program. Data used for these CL and Affy arrays are accessible for free download through the National Center for Biotechnology Information\'s Gene Expression Omnibus (NCBI GEO) via series accession number GSE5877.

We also compared our results to data from our studies examining the influence of sex in adult MRL/lpr and NOD mice (*n* = 15--18/sex/strain),[@i1552-5783-60-6-2181-b30] and 2 weeks of P or T treatment of nonautoimmune, ovariectomized BALB/c mice (*n* = 5--6 mice/condition/experiment),[@i1552-5783-60-6-2181-b31] on lacrimal gland gene expression. The sex- and hormone-related data are available through the NCBI GEO via series accession numbers GSE5876 and GSE3995, respectively.

Results {#s3}
=======

T Influence on Gene Expression in Lacrimal Glands of Female MRL/lpr and NOD Mice {#s3a}
--------------------------------------------------------------------------------

To determine the effect of androgen treatment on gene expression in lacrimal glands of autoimmune mice, tissues were obtained from female MRL/lpr and NOD mice (*n* = 7--18 mice/strain/treatment) following 20 to 21 days of exposure to P or T. Glands were pooled according to treatment and strain (*n* = 4--12 glands/samples/strain/treatment; *n* = 3 samples/treatment group), processed for isolation of total RNA, and analyzed for differentially expressed mRNAs using CL Bioarrays and Affy GeneChips. Microarray data were evaluated with Geospiza bioinformatics software.

Our results with CL and Affy microarrays showed that testosterone treatment has a significant influence on expression of thousands of genes in lacrimal glands of MRL/lpr and NOD mice ([Table 1](#i1552-5783-60-6-2181-t01){ref-type="table"}). Androgen exposure increased (↑) the activity of genes, such as cytochrome P450, family 2, subfamily j, polypeptide 13 (Cyt), and decreased (↓) that of pancreatic lipase--related protein 1 (PL) in both strains ([Tables 2](#i1552-5783-60-6-2181-t02){ref-type="table"}, [3](#i1552-5783-60-6-2181-t03){ref-type="table"}). These two genes also are regulated in the same manner in lacrimal tissues of nonautoimmune female BALB/c mice (Cyt = 9.9-fold ↑; PL = 81.1-fold ↓; NCBI GEO GSE3995).[@i1552-5783-60-6-2181-b31]

###### 

Effect of T on Gene Expression in Lacrimal Glands of Female MRL/lpr and NOD Mice

  **Mouse Strain/Array**    **Genes ↑**   **Genes ↓**   **Total Genes**
  ------------------------ ------------- ------------- -----------------
  MRL/lpr                                              
   CL                          1890          1708            3598
   Affy                        1120          1530            2650
  NOD                                                  
   CL                          1474          2275            3749
   Affy                        1102          1150            2252

Data were evaluated without log transformation. The expression of listed genes was significantly (*P* \< 0.05) up (↑)- or down (↓)-regulated by T treatment.

###### 

T Influence on Gene Expression in Lacrimal Glands of Female MRL/lpr Mice

  **Accession \#**   **Gene**                                                             **Ratio**   ***P*** **Value**   **Ontology**
  ------------------ -------------------------------------------------------------------- ----------- ------------------- -----------------------------------------------------------------------
  T\>P, CL                                                                                                                
   NM_145548         Cytochrome P450, family 2, subfamily j, polypeptide 13               528.0       0.0000              Oxidation-reduction process
   NM_010643         Kallikrein 1-related peptidase b24                                   273.1       0.0000              Proteolysis
   NM_001042711.2    Amylase 2, pancreatic                                                204.6       0.0087              Endohydrolysis
   NM_146592         Olfactory receptor 1086                                              151.5       0.0062              Signal transduction
   NM_020277         Transient receptor potential cation channel, subfamily M, member 5   142.2       0.0087              Transport
   NM_146805         Olfactory receptor 907                                               121.9       0.0074              Signal transduction
   BB149074          Oxysterol binding protein-like 3                                     111.5       0.0004              Transport
   NM_016672         Dopa decarboxylase                                                   109.6       0.0154              Cellular amino acid metabolic process
  T\>P, Affy                                                                                                              
   NM_020268         Kallikrein 1-related peptidase b27                                   2894.0      0.0008              Proteolysis
   NM_019515         Neuromedin U                                                         656.7       0.0006              Energy homeostasis
   NM_017390         Seminal vesicle secretory protein 2                                  328.6       0.0190              Fertilization
   BC016446          Cytochrome P450, family 2, subfamily j, polypeptide 13               310.0       0.0018              Oxidation-reduction process
   AK020349          Seminal vesicle secretory protein IV                                 284.2       0.0002              Fertilization
   NM_010643         Kallikrein 1-related peptidase b24                                   268.0       0.0000              Proteolysis
   M16360            Major urinary protein V                                              222.1       0.0011              Transport
   AY079153          Melanocortin 2 receptor accessory protein                            150.2       0.0001              Positive regulation of camp biosynthetic process
  P\>T, CL                                                                                                                
   NM_018874         Pancreatic lipase related protein 1                                  21.0        0.0049              Lipid metabolic process
   NM_024427         Tropomyosin 1, α                                                     18.8        0.0017              In utero embryonic development
   NM_011105         Polycystin and REJ                                                   15.8        0.0003              Transport
   NM_009714         Asialoglycoprotein receptor 1                                        11.4        0.0024              Endocytosis
   AK002477          Plasma membrane proteolipid                                          10.6        0.0009              Transport
   NM_026123         Unc-50 homolog                                                       9.5         0.0002              Protein transport
   BC018468          Endoplasmic reticulum lectin 1                                       9.0         0.0053              ER-associated protein catabolic process
   AW492955          doublecortin domain containing 2a                                    8.0         0.0015              Neuron migration
  P\>T, Affy                                                                                                              
   NM_018874         Pancreatic lipase related protein 1                                  30.1        0.0008              Lipid metabolic process
   M30697            ATP-binding cassette, sub-family B, member 1A                        28.2        0.0005              ATP catabolic process
   BC005555          Prolactin receptor                                                   22.1        0.0009              Activation of transmembrane receptor protein tyrosine kinase activity
   NM_008109         Growth differentiation factor 5                                      15.6        0.0004              Cell-cell signaling
   U09362            Asialoglycoprotein receptor 1                                        13.0        0.0012              Endocytosis
   NM_013669         Synaptosomal-associated protein 91                                   12.9        0.0036              Establishment or maintenance of cell polarity
   AF147785          Lost on transformation protein 1                                     11.6        0.0043              Regulation of gene expression
   BC024580          Carboxymethylenebutenolidase-like                                    7.5         0.0078              Hydrolase activity

Accession numbers are the sequence identities of gene fragments expressed on the CL and Affy microarrays. These sequences appear in the nucleotide database of the NCBI. Relative ratios were determined by comparing the degree of gene expression in lacrimal glands from P- and T-treated female MRL/lpr mice. Ratios were calculated from nontransformed data.

###### 

T Impact on Gene Expression in Lacrimal Glands of Female NOD Mice

  **Accession \#**   **Gene**                                                              **Ratio**   ***P*** **Value**   **Ontology**
  ------------------ --------------------------------------------------------------------- ----------- ------------------- -----------------------------------------------------------------------
  T\>P, CL                                                                                                                 
   NM_010639         Kallikrein 1                                                          216.7       0.0237              Proteolysis
   NM_145548         Cytochrome P450, family 2, subfamily j, polypeptide 13                212.2       0.0162              Oxidation-reduction process
   NM_010643         Kallikrein 1-related peptidase b24                                    91.1        0.0221              Proteolysis
   NM_010644         Kallikrein 1-related peptidase b26                                    72.9        0.0237              Proteolysis
   BC002033          RAD50 homolog                                                         52.0        0.0050              DNA recombination
   NM_008957         Patched homolog 1                                                     48.5        0.0071              Signal transduction
   BC012259          Major urinary protein 2                                               47.9        0.0026              Pheromone binding
   AK004371          RAS-like, family 11, member A                                         42.5        0.0007              GTP catabolic process
  T\>P, Affy                                                                                                               
   BC016446          Cytochrome P450, family 2, subfamily j, polypeptide 13                618.5       0.0125              Oxidation-reduction process
   U82380            Submaxillary gland androgen regulated protein 2                       361.9       0.0003              Response to toxin
   NM_010644         Kallikrein 1-related peptidase b26                                    247.1       0.0145              Proteolysis
   BC026378          Kallikrein 1-related peptidase b1                                     207.3       0.0004              Proteolysis
   NM_133997         Apolipoprotein F                                                      154.3       0.0035              Lipid metabolic process
   BC009165          Thyroid hormone responsive SPOT14 homolog                             95.6        0.0001              Transcription, DNA-dependent
   AB065134          Monooxygenase, DBH-like 2                                             90.4        0.0114              Catecholamine metabolic process
   AY079153          Melanocortin 2 receptor accessory protein                             84.2        0.0060              Positive regulation of camp biosynthetic process
  P\>T, CL                                                                                                                 
   NM_018874         Pancreatic lipase related protein 1                                   1877.1      0.0475              Lipid metabolic process
   NM_011105         Polycystin and REJ                                                    38.3        0.0001              Transport
   AK002477          Plasma membrane proteolipid                                           33.6        0.0005              Transport
   NM_011857         Teneurin-3                                                            31.1        0.0002              Signal transduction
   NM_010726         Phytanoyl-CoA hydroxylase                                             24.7        0.0001              Fatty acid α-oxidation
   NM_026754         Unique cartilage matrix-associated protein                            24.4        0.0197              Negative regulation of osteoblast differentiation
   NM_019752         HtrA serine peptidase 2                                               24.4        0.0009              Proteolysis
   NM_146242         Leucine rich repeat containing 10                                     24.3        0.0001              Transport
  P\>T, Affy                                                                                                               
   NM_018874         Pancreatic lipase related protein 1                                   1462.8      0.0059              Lipid metabolic process
   AF147785          Lost on transformation protein 1                                      33.2        0.0002              Regulation of gene expression
   BC005555          Prolactin receptor                                                    23.4        0.0095              Activation of transmembrane receptor protein tyrosine kinase activity
   NM_010726         Phytanoyl-CoA hydroxylase                                             21.8        0.0096              Fatty acid α-oxidation
   AK014353          KH domain containing, RNA binding, signal transduction associated 3   13.5        0.0000              Transcription, DNA-dependent
   BC011209          Major facilitator superfamily domain containing 7C                    13.5        0.0019              Transport
   AY061807          Calmodulin-like 4                                                     13.1        0.0002              Calcium ion binding
   NM_134094         Neurocalcin delta                                                     13.0        0.0009              Calcium-mediated signaling

Genes with known ontologies are listed. Relative ratios were calculated by comparing the degree of gene expression in lacrimal glands from P- and T-treated female NOD mice. Ratios were generated from nontransformed data.

Examples of other genes upregulated in lacrimal glands of MRL/lpr mice, such as oxysterol binding protein-like 3, olfactory receptor 1086, and dopa decarboxylase ([Table 2](#i1552-5783-60-6-2181-t02){ref-type="table"}), also were very highly upregulated by 39.4-, 36.8-, and 58.6-fold amounts, respectively, in NOD lacrimal tissues. In contrast, the gene expression for cathepsin S, which is significantly elevated in the tears of Sjögren syndrome patients,[@i1552-5783-60-6-2181-b32] was significantly (*P* \< 0.05) decreased by testosterone in female MRL/lpr lacrimal glands (CL = 1.53-fold ↓; Affy = 1.88-fold ↓), but increased by androgen treatment in those of female NOD mice (CL = 3.87-fold ↑; Affy = 3.23-fold ↑). A similar pattern was found for *moesin* gene expression, which was reduced by T in female MRL/lpr lacrimal glands (Affy = 3.19-fold ↓), but increased by androgen exposure in lacrimal tissues of female NOD mice (Affy = 3.39-fold ↑). Other genes were regulated by T in the lacrimal tissue of only one strain (e.g., NOD, spleen tyrosine kinase \[Syk\]; CL = 3.1-fold ↑).

As we[@i1552-5783-60-6-2181-b30],[@i1552-5783-60-6-2181-b33][@i1552-5783-60-6-2181-b34]--[@i1552-5783-60-6-2181-b35] and other investigators[@i1552-5783-60-6-2181-b36][@i1552-5783-60-6-2181-b37][@i1552-5783-60-6-2181-b38]--[@i1552-5783-60-6-2181-b39] have discovered, the vast majority of lacrimal gland genes in MRL/lpr and NOD female mice, which were identified as differentially expressed by the CL and Affy microarrays, were unique to each platform. Indeed, as demonstrated in [Table 4](#i1552-5783-60-6-2181-t04){ref-type="table"}, only 8.5% to 11.1% (T\>P), and 7.3% to 16.8% (P\>T) of the regulated genes were found by both microarrays. These data showed that there are significant differences in the ability of these platforms to detect differential gene expression.

###### 

Comparative Gene Expression Between CL and Affy Microarrays

                                             **Genes T\>P**   **Genes P\>T**   **Total Genes**
  ------------------------------------------ ---------------- ---------------- -----------------
  MRL/lpr                                                                      
   CL                                                                          
    Unique CL genes, not expressed by Affy   1724             1284             3008
   Affy                                                                        
    Unique Affy genes, not expressed by CL   943              1490             2433
   CL vs. Affy                                                                 
    Genes changed in same direction          143              216              359
    Genes changed in opposite direction                                        16
  NOD                                                                          
   CL                                                                          
    Unique CL genes, not expressed by Affy   1326             2091             3417
   Affy                                                                        
    Unique Affy genes, not expressed by CL   932              973              1905
   CL vs. Affy                                                                 
    Genes changed in same direction          147              152              299
    Genes changed in opposite direction                                        13

Data were evaluated without log transformation. Genes identified as "unique" were significantly (*P* \< 0.05) increased on one, but not the other, microarray platform. The phrase "Genes changed in the same (or opposite) direction" means that the results were significant (*P* \< 0.05) on both platforms.

This low concordance in gene identification appears to be due to intrinsic variations in multiple aspects of platform design, as well as to the inherent instability of lists of significantly changed genes based upon *P* value cutoffs.[@i1552-5783-60-6-2181-b36][@i1552-5783-60-6-2181-b37][@i1552-5783-60-6-2181-b38][@i1552-5783-60-6-2181-b39]--[@i1552-5783-60-6-2181-b40] The result is that CL and Affy microarrays, both of which have documented accuracy and reproducibility, seem to measure different things.[@i1552-5783-60-6-2181-b38] Most gene expression differences revealed by each platform are thought to be biologically correct, and these variations cannot be attributed to technological differences.[@i1552-5783-60-6-2181-b37],[@i1552-5783-60-6-2181-b38]

Comparison of gene expression between the lacrimal glands of P-treated MRL/lpr and NOD mice demonstrated that 587 genes were in common (CL). The alternate comparison (i.e., MRL/lpr, T\>P; NOD, T\>P) revealed 559 genes in common (CL).

T Effect on Immune-Related Ontologies in Lacrimal Glands of Female MRL/lpr, NOD and BALB/c Mice {#s3b}
-----------------------------------------------------------------------------------------------

T exerted a significant influence on the expression of a large number of immune-related gene ontologies in the lacrimal glands of female MRL/lpr and NOD mice. Many of these hormone responses were identified by CL and Affy platforms ([Tables 5](#i1552-5783-60-6-2181-t05){ref-type="table"}, [6](#i1552-5783-60-6-2181-t06){ref-type="table"}).

###### 

T Downregulation of Immune-Related Gene Ontologies in Lacrimal Glands of Female MRL/lpr Mice

  **Ontology**                                                   **CL Genes** ↓   **Affy Genes** ↓   **CL** ***z*****-score**   **Affy** ***z*****-score**
  -------------------------------------------------------------- ---------------- ------------------ -------------------------- ----------------------------
  Biological process                                                                                                            
   Immune system process                                         166              130                7.27                       3.97
   Immune response                                               90               67                 5.45                       2.65
   Defense response                                              89                                  4.73                       
   Regulation of immune system process                           79               68                 3.9                        2.72
   Leukocyte activation                                          65               54                 4.58                       3.06
   Immune system development                                     61                                  2.98                       
   Hemopoietic or lymphoid organ development                     58                                  3.02                       
   Lymphocyte activation                                         55               44                 4.11                       2.4
   Positive regulation of immune system process                  55               47                 3.33                       2.12
   Response to cytokine stimulus                                 47               35                 6.4                        3.76
   Innate immune response                                        46               35                 4.75                       2.82
   Induction of apoptosis                                        45                                  2.82                       
   Regulation of immune response                                 43                                  2.31                       
   Cytokine production                                           41                                  3.03                       
   Regulation of defense response                                41                                  3.6                        
   Immune effector process                                       39                                  2.56                       
   Inflammatory response                                         39                                  2.51                       
   Leukocyte differentiation                                     38                                  3.13                       
   T cell activation                                             38                                  3.46                       
   Positive regulation of immune response                        37                                  2.82                       
   Positive regulation of intracellular protein kinase cascade   36                                  2.84                       
   Regulation of leukocyte activation                            34               34                 2.87                       3.2
   Regulation of cytokine production                             33                                  2.23                       
   Regulation of lymphocyte activation                           32               30                 3.13                       2.92
   Cellular response to cytokine stimulus                        31               25                 4.45                       2.98
   Leukocyte proliferation                                       31               23                 4.19                       2.22
   Activation of immune response                                 30               24                 2.98                       2.03
   Lymphocyte proliferation                                      30               22                 4.08                       2.08
   Positive regulation of defense response                       29                                  3.61                       
   I-κb kinase/NF-κb cascade                                     25                                  3.54                       
   Positive regulation of leukocyte activation                   25               24                 3.23                       2.96
   Positive regulation of lymphocyte activation                  24               22                 3.42                       2.77
   Regulation of T-cell activation                               24               21                 2.91                       2.44
   Cytokine-mediated signaling pathway                           23                                  2.99                       
   Immune response-activating signal transduction                23               20                 2.24                       2.03
   Immune response-regulating signaling pathway                  23                                  2.13                       
   Regulation of leukocyte proliferation                         23               20                 3.44                       2.69
   Positive regulation of cytokine production                    22                                  3.22                       
   Regulation of lymphocyte proliferation                        22                                  3.27                       
   B-cell activation                                             21                                  2.16                       
   Regulation of innate immune response                          21                                  2.24                       
   T-cell differentiation                                        20                                  2.22                       
   T-cell proliferation                                          20                                  3.26                       
   Activation of innate immune response                          18                                  2.79                       
   Cytokine biosynthetic process                                 15                                  2.35                       
   Cytokine metabolic process                                    15                                  2.35                       
   Innate immune response-activating signal transduction         17                                  2.55                       
   Leukocyte migration                                           17                                  2.04                       
   Myeloid leukocyte activation                                  14                                  2.25                       
   Myeloid leukocyte differentiation                             16                                  2.4                        
   Positive regulation of I-κb kinase/NF-κb cascade              18                                  3.38                       
   Positive regulation of innate immune response                 19                                  2.29                       
   Positive regulation of leukocyte proliferation                18                                  3.56                       
   Positive regulation of lymphocyte proliferation               17                                  3.37                       
   Positive regulation of mononuclear cell proliferation         17                                  3.31                       
   Positive regulation of T-cell activation                      18               18                 3.21                       3.29
   Regulation of I-κb kinase/NF-κb cascade                       19                                  3.18                       
   Regulation of inflammatory response                           17                                  2.08                       
   Regulation of innate immune response                                           19                                            2.06
   Regulation of lymphocyte proliferation                                         19                                            2.5
   Regulation of T-cell proliferation                            15                                  2.73                       
   Toll-like receptor signaling pathway                          15                                  2.15                       
  Molecular function                                                                                                            
   Cytokine binding                                              16                                  2.22                       
   Cytokine receptor activity                                    10                                  2.35                       
   Chemokine receptor binding                                    9                10.00              2.57                       3.23
   Antigen binding                                                                8.00                                          5.16
   Chemokine activity                                            7                                   2.11                       
   NF-κb binding                                                 5                                   2                          
  Cellular components                                                                                                           
   MHC protein complex                                           5                                   2.38                       

Biological process (≥20 genes/ontology), molecular function (≥5 genes/ontology) and cellular component (≥5 genes/ontology) immune ontologies were identified after the analysis of nontransformed CL and Affy data. These immune ontologies were upregulated in lacrimal gland samples from P-treated female mice, and by extension, downregulated in lacrimal gland tissues from androgen-treated mice. A *z*-score is a statistical rating of the relative expression of genes, and shows how greatly they are over- or underrepresented in a specific gene list.[@i1552-5783-60-6-2181-b41] Positive *z*-scores represent a higher number of genes meeting the criterion than is anticipated by chance, and values \>2.0 are significant. CL Genes ↓, number of genes downregulated, as calculated with a CL Bioarray; Affy Genes ↓, number of genes downregulated, as determined with Affy GeneChips; *z*-score, specific score for the down-regulated genes in the CL- and Affy-related tissues.

###### 

T Upregulation of Immune-Related Gene Ontologies in Lacrimal Glands of Female NOD Mice

  **Ontology**                                                                                             **CL Genes ↑**   **Affy Genes ↑**   **CL** ***z*****-Score**   **Affy** ***z*****-Score**
  -------------------------------------------------------------------------------------------------------- ---------------- ------------------ -------------------------- ----------------------------
  Biological process                                                                                                                                                      
   Immune system process                                                                                   192              137                13.29                      9.08
   Immune response                                                                                         127              85                 13.54                      8.8
   Defense response                                                                                        115              80                 10.91                      7.13
   Regulation of immune system process                                                                     111              77                 11.05                      7.28
   Leukocyte activation                                                                                    87               61                 10.52                      7.15
   Positive regulation of immune system process                                                            86               65                 10.98                      8.35
   Regulation of immune response                                                                           77               50                 10.88                      6.86
   Lymphocyte activation                                                                                   72               53                 9.2                        6.77
   Immune effector process                                                                                 71               46                 11.16                      7.07
   Immune system development                                                                               69               50                 6.12                       4.13
   Innate immune response                                                                                  62               44                 10.06                      7.31
   Positive regulation of immune response                                                                  62               44                 10.1                       7.34
   Cytokine production                                                                                     59               37                 8.52                       4.88
   Regulation of leukocyte activation                                                                      54               37                 9.16                       6.14
   T-cell activation                                                                                       53               40                 8.5                        6.65
   Inflammatory response                                                                                   51               30                 6.57                       2.85
   Regulation of cytokine production                                                                       51               33                 7.85                       4.74
   Leukocyte differentiation                                                                               49               35                 7.11                       4.95
   Regulation of defense response                                                                          49               33                 6.9                        4.27
   Regulation of lymphocyte activation                                                                     48               34                 8.63                       6.06
   Leukocyte mediated immunity                                                                             47               28                 9.82                       5.53
   Activation of immune response                                                                           44               34                 8.01                       6.84
   Positive regulation of leukocyte activation                                                             43               30                 9.99                       6.75
   Regulation of immune effector process                                                                   43               21                 9.15                       3.79
   Lymphocyte mediated immunity                                                                            40               26                 9.36                       6.05
   Positive regulation of lymphocyte activation                                                            40               27                 9.75                       6.21
   Chemotaxis                                                                                              39               29                 3.94                       2.61
   Response to cytokine stimulus                                                                           39               30                 5.89                       4.52
   Adaptive immune response                                                                                38               28                 8.19                       6.22
   Adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin   38               28                 8.36                       6.46
   Immune response-regulating signaling pathway                                                            38               29                 7.65                       6.61
   Leukocyte proliferation                                                                                 38               27                 7.5                        5.21
   Lymphocyte differentiation                                                                              38               27                 6.89                       4.73
   Immune response-activating signal transduction                                                          37               29                 7.51                       6.7
   Lymphocyte proliferation                                                                                37               27                 7.41                       5.37
   Regulation of T-cell activation                                                                         35               26                 7.42                       5.81
   Positive regulation of defense response                                                                 32               25                 5.68                       4.8
   Regulation of leukocyte proliferation                                                                   32               21                 7.54                       4.68
   B-cell activation                                                                                       31               25                 6.32                       5.38
   Positive regulation of cytokine production                                                              31                                  7.33                       
   Regulation of innate immune response                                                                    31               21                 6.42                       4.33
   Regulation of lymphocyte proliferation                                                                  31               21                 7.39                       4.82
   Positive regulation of immune effector process                                                          30                                  9.08                       
   Positive regulation of T-cell activation                                                                30               22                 8.82                       6.53
   Regulation of leukocyte mediated immunity                                                               30                                  8.99                       
   T-cell differentiation                                                                                  30                                  6.47                       
   Negative regulation of immune system process                                                            28               18                 5.77                       3.55
   Cellular response to cytokine stimulus                                                                  26               23                 4.19                       4.15
   Positive regulation of leukocyte proliferation                                                          26               15                 7.74                       3.88
   Regulation of adaptive immune response                                                                  26                                  7.9                        
   Regulation of adaptive immune response based on somatic recombination of immune receptors built from    26                                  7.99                       
   T-cell proliferation                                                                                    26               16                 6.44                       3.65
   Myeloid leukocyte activation                                                                            25                                  7.58                       
   Positive regulation of innate immune response                                                           25               18                 5.28                       4.02
   Positive regulation of lymphocyte proliferation                                                         25               15                 7.58                       4.04
   Regulation of lymphocyte mediated immunity                                                              25                                  7.93                       
   Regulation of lymphocyte differentiation                                                                24                                  7.77                       
   B-cell mediated immunity                                                                                23                                  7.08                       
   Immune response-regulating cell surface receptor signaling pathway                                      23                                  8.11                       
   Antigen processing and presentation                                                                     22               20                 9.6                        9.59
   I-κb kinase/NF-κb cascade                                                                               22               22                 3.68                       4.77
   Immune response-activating cell surface receptor signaling pathway                                      22                                  7.86                       
   Immunoglobulin mediated immune response                                                                 22                                  6.74                       
   Regulation of B-cell activation                                                                         22                                  7                          
   Cell activation involved in immune response                                                             21                                  5.39                       
   Cytokine biosynthetic process                                                                           21                                  5.59                       
   Cytokine metabolic process                                                                              21                                  5.59                       
   Cytokine-mediated signaling pathway                                                                     21               16                 3.4                        2.5
   Leukocyte activation involved in immune response                                                        21                                  5.39                       
   Positive regulation of adaptive immune response                                                         21                                  8.66                       
   Positive regulation of adaptive immune response based on somatic recombination of immune receptors b    21                                  8.66                       
   Leukocyte migration                                                                                     20                                  4                          
   Positive regulation of leukocyte mediated immunity                                                      20                                  8.4                        
   Positive regulation of lymphocyte mediated immunity                                                     20                                  8.4                        
   Regulation of T-cell proliferation                                                                      20                                  5.67                       
   Activation of innate immune response                                                                    19               17                 4.1                        4.51
   Leukocyte mediated cytotoxicity                                                                         19                                  7.39                       
   Positive regulation of lymphocyte differentiation                                                       19                                  8.42                       
   Innate immune response-activating signal transduction                                                   18               17                 3.83                       4.62
   Positive regulation of B-cell activation                                                                18                                  7.35                       
   Regulation of T-cell differentiation                                                                    18                                  6.28                       
   α-β T-cell activation                                                                                   17                                  5.05                       
   Positive regulation of I-κb kinase/NF-κb cascade                                                        17               13                 3.94                       3.27
   Positive regulation of T-cell proliferation                                                             17                                  6.39                       
   Regulation of I-κb kinase/NF-κb cascade                                                                 17               16                 3.41                       3.99
   Regulation of inflammatory response                                                                     17                                  2.98                       
   T-cell differentiation in thymus                                                                        17                                  6.18                       
   B-cell differentiation                                                                                  16                                  5.5                        
   Leukocyte chemotaxis                                                                                    16                                  4.47                       
   Myeloid leukocyte differentiation                                                                       16                                  3.28                       
   Positive regulation of T-cell differentiation                                                           16                                  7.45                       
   Toll-like receptor signaling pathway                                                                    16                                  3.38                       
   Negative regulation of cytokine production                                                              14                                  3.93                       
  Molecular function                                                                                                                                                      
   Cytokine activity                                                                                       29                                  4.88                       
   Cytokine receptor binding                                                                               24                                  3.36                       
   Cytokine binding                                                                                        20                                  4.68                       
   Chemokine receptor binding                                                                              11               8                  4.46                       3.21
   Chemokine activity                                                                                      10               6                  4.66                       2.59
   Antigen binding                                                                                         9                10                 6.9                        8.35
   Cytokine receptor activity                                                                              8                                   2.06                       
   Chemokine binding                                                                                       6                                   3.33                       
   Chemokine receptor activity                                                                             6                                   3.64                       
   C-C chemokine binding                                                                                   5                                   3.48                       
   C-C chemokine receptor activity                                                                         5                                   3.68                       
   MHC protein binding                                                                                     5                                   5.31                       
   CCR chemokine receptor binding                                                                          4                                   3.6                        
   Chemoattractant activity                                                                                4                                   2.9                        
   MHC class I protein binding                                                                             4                                   4.75                       
  Cellular components                                                                                                                                                     
   MHC protein complex                                                                                     11               11                 7.99                       8.96
   T cell receptor complex                                                                                 7                                   8                          
   MHC class II protein complex                                                                            6                6                  6.24                       6.98
   α-β T-cell receptor complex                                                                             5                                   7.32                       
   CD40 receptor complex                                                                                   5                                   5.3                        
   Immunological synapse                                                                                   5                                   4.11                       

Biological process (≥20 genes/ontology), molecular function (≥5 genes/ontology) and cellular component (≥5 genes/ontology) immune ontologies were identified after the evaluation of nontransformed CL and Affy data. CL Genes ↑, number of genes up-regulated, as identified with a CL Bioarray; Affy Genes ↑, number of genes up-regulated, as found with Affy GeneChips; z-score, specific score for the up-regulated genes in the CL and Affy related tissues.

As demonstrated in [Table 5](#i1552-5783-60-6-2181-t05){ref-type="table"}, androgen administration downregulated the expression of over 60 immune-associated biological process ontologies (≥20 genes/ontology) in lacrimal tissues of female MRL/lpr mice, including those related to immune system processes, lymphocyte activation, cytokine production, and inflammatory response. In contrast, T increased the expression of all of these same immune ontologies, as well as more, in lacrimal glands of female NOD mice ([Table 6](#i1552-5783-60-6-2181-t06){ref-type="table"}). These changes were accompanied by down- and upregulation of immune-related molecular function (e.g., chemokine activity) and cellular component (e.g., MHC protein complex) ontologies (≥5 genes/ontology) in lacrimal tissues of MRL/lpr and NOD mice, respectively.

Some genes represented within these immune ontologies were the same (e.g., MRL/lpr ↓ and NOD ↑: chemokine \[C-X-C motif\] ligand 9 \[Cxcl9\], IL-1β, and toll-like receptors 1 and 2 \[TLR 1 and 2\]), but most were not. For example, T decreased the expression of 96 immune-response genes (CL) in lacrimal glands of MRL/lpr mice ([Table 7](#i1552-5783-60-6-2181-t07){ref-type="table"}), but the majority of these genes were different than the 133 genes (CL) upregulated in NOD mouse tissues ([Table 8](#i1552-5783-60-6-2181-t08){ref-type="table"}). Despite these differences, the androgen-regulated immune-response genes were predominantly inflammatory in nature. Thus, T downregulated the expression of 41 inflammatory genes in MRL/lpr lacrimal tissues and 23 of these were the same as in [Table 7](#i1552-5783-60-6-2181-t07){ref-type="table"}. Further, androgen administration increased the expression of 52 inflammatory genes in NOD lacrimal glands and 36 of these were identical to those in [Table 8](#i1552-5783-60-6-2181-t08){ref-type="table"}.

###### 

T-Induced Decrease of Gene Expression in the Immune Response Ontology in Lacrimal Glands From Female MRL/lpr Mice

  **Gene**                                                                 **CL Ratio**   **Affy Ratio**   **CL** ***P*** **Value**   **Affy** ***P*** **Value**
  ------------------------------------------------------------------------ -------------- ---------------- -------------------------- ----------------------------
  Indoleamine 2,3-dioxygenase 1                                            4.55                            0.0073                     
  Guanylate binding protein 2\*                                            4.31           2.63             0.0016                     0.0004
  Linker for activation of T cells family, member 2\*                      4.09                            0.0024                     
  Ectonucleotide pyrophosphatase/phosphodiesterase                                        3.61                                        0.0033
  Synaptic cell adhesion molecule 1                                                       3.52                                        0.0009
  Chemokine (C-X-C motif) ligand 11                                        3.12                            0.0185                     
  Properdin                                                                               3.4                                         0.0242
  Chemokine (C-X-C motif) ligand 16                                        3.01           2.08             0.0003                     0.0377
  Histocompatibility 2, class II antigen A, β1                                            2.98                                        0.0037
  Complement component 3                                                   2.94           2.53             0.0015                     0.0052
  C-type lectin domain family 2, member d                                  2.9            1.9              0.0007                     0.0407
  Toll-like receptor 4, mRNA                                               2.89                            0.0094                     
  Interleukin 1 receptor accessory protein, transcript variant 2           2.81                            0.0021                     
  Protein tyrosine phosphatase, receptor type, C, transcript variant 2\*   2.8            2.05             0.0155                     0.0159
  Dual specificity phosphatase 6                                                          2.78                                        0.0066
  Chemokine (C-C motif) ligand 6                                           2.77           2.33             0.0010                     0.0304
  Interleukin enhancer binding factor 2                                    2.77           2.94             0.0260                     0.0320
  Fc receptor, IgG, α chain transporter                                    2.73                            0.0086                     
  Bmi1 polycomb ring finger oncogene                                       2.72           2.02             0.0253                     0.0106
  Immunoglobulin heavy chain complex\*                                     2.71           4                0.0248                     0.0033
  Ectonucleotide pyrophosphatase/phosphodiesterase 2                       2.68                            0.0037                     
  Immunoglobulin joining chain                                             2.65                            0.0001                     
  Presenilin 1                                                             2.61                            0.0069                     
  Complement component 1, s subcomponent, transcript variant 1             2.58                            0.0013                     
  2-5 oligoadenylate synthetase-like 2\*                                   2.56                            0.0051                     
  Fc receptor, IgE, high affinity I, gamma polypeptide                                    2.49                                        0.0037
  Guanylate-binding protein 10                                                            2.44                                        0.0019
  SAM and SH3 domain containing 3\*                                        2.42                            0.0070                     
  CD79B antigen\*                                                          2.39           2.69             0.0154                     0.0050
  Vav 1 oncogene\*                                                         2.39                            0.0314                     
  Interferon inducible GTPase 1                                            2.38           1.58             0.0093                     0.0438
  Chemokine (C-C motif) receptor 2                                         2.36           1.61             0.0024                     0.0404
  Protein kinase RICK                                                      2.36                            0.0008                     
  Strain SJL/J small inducible cytokine A4                                 2.32                            0.0032                     
  Interleukin 33                                                           2.31           2.45             0.0006                     0.0114
  Tumor necrosis factor, α-induced protein 8-like 2                        2.31                            0.0405                     
  Lymphocyte cytosolic protein 1                                                          2.28                                        0.0204
  Serine (or cysteine) peptidase inhibitor, clade G, member 1                             2.28                                        0.0009
  Yamaguchi sarcoma viral (v-yes-1) oncogene homolog                                      2.28                                        0.0165
  Chemokine (C-X-C motif) ligand 13                                        2.3            2.38             0.0020                     0.0036
  Guanylate binding protein 3\*                                            2.27                            0.0155                     
  C-type lectin domain family 7, member a                                  2.24           2.87             0.0015                     0.0011
  Chemokine (C-X-C motif) ligand 9\*                                       2.22           2.07             0.0260                     0.0242
  Phospholipid scramblase 1                                                2.21                            0.0070                     
  Glutathione peroxidase 2                                                 2.19                            0.0046                     
  Annexin A3                                                               2.18           1.89             0.0202                     0.0100
  A-synuclein                                                              2.15                            0.0012                     
  Guanylate binding protein 4                                              2.15                            0.0072                     
  Killer cell lectin-like receptor family E member 1                       2.15                            0.0081                     
  Interferon induced with helicase C domain 1                                             2.15                                        0.0198
  Transporter 1, ATP-binding cassette, sub-family B4                       2.13                            0.0244                     
  Dual specificity phosphatase 6                                           2.07                            0.0183                     
  Nuclear receptor subfamily 1, group H, member 3                          2.07                            0.0093                     
  Vitronectin                                                              2.07                            0.0457                     
  Toll-like receptor 3                                                     2.06                            0.0029                     
  Syntaxin binding protein 2                                                              2.06                                        0.0229
  CD55 antigen                                                             2.04                            0.0146                     
  Toll-like receptor 2                                                     2.02           3.51             0.0104                     0.0035
  High mobility group box 1                                                               2.02                                        0.0012
  Guanylate binding protein 6                                              2                               0.0040                     

Relative ratios were calculated from CL and Affy data by comparing the degree of gene expression in lacrimal glands from P- versus T-treated female MRL/lpr mice. Listed CL genes were increased ≥2-fold.

Genes were found to be upregulated in lacrimal glands of female NOD mice treated with T ([Table 8](#i1552-5783-60-6-2181-t08){ref-type="table"}).

###### 

T-Stimulated Increase of Gene Expression in the Immune Response Ontology in Lacrimal Glands From Female NOD Mice

  **Gene**                                                                   **CL Ratio**   **Affy Ratio**   **CL** ***P*** **Value**   **Affy** ***P*** **Value**
  -------------------------------------------------------------------------- -------------- ---------------- -------------------------- ----------------------------
  Chemokine (C-X-C motif) ligand 10                                          10.71          4.86             0.0056                     0.0183
  Forkhead box P3                                                            10.7                            0.0007                     
  MHC I=H-2Kd homolog                                                        10.39                           0.0001                     
  Chemokine (C-X-C motif) ligand 9\*                                         10.01          33.35            0.0066                     0.0021
  Adenosine A2b receptor                                                     9.81           3.87             0.0145                     0.0002
  Histocompatibility 2, K1, K region                                         9.71                            0.0000                     
  Interferon regulatory factor 7                                             9.33           4.15             0.0198                     0.0002
  Interleukin 21                                                             8.12                            0.0031                     
  Tripartite motif-containing 25                                             8.01                            0.0205                     
  Chemokine (C-C motif) ligand 5                                             7.21           15.38            0.0192                     0.0103
  Histocompatibility 2, blastocyst                                           7.2                             0.0075                     
  Chemokine (C-C motif) ligand 8                                             7.06           7.68             0.0017                     0.0004
  Lymphotoxin B                                                              6.63           8.35             0.0115                     0.0082
  Guanylate binding protein 2\*                                              6.54           6.6              0.0204                     0.0029
  CD86 antigen                                                               6.37           4.34             0.0035                     0.0013
  Interferon regulatory factor 8, mRNA (cDNA clone MGC:6194 IMAGE:3487214)   6.35           5.34             0.0026                     0.0068
  CD247 antigen                                                              6.19                            0.0036                     
  Guanylate-binding protein 10                                               6.12                            0.0279                     
  Complement component 4B                                                    6.05           4.46             0.0054                     0.0044
  Chemokine (C motif) ligand 1                                               5.94                            0.0247                     
  Transporter 1, ATP-binding cassette, sub-family B                          5.84           7.76             0.0009                     0.0000
  Chemokine (C-C motif) receptor 7                                           5.75                            0.0411                     
  Immunity-related GTPase family M member 1                                  5.72           5.63             0.0051                     0.0074
  Myxovirus (influenza virus) resistance 2)                                  5.72                            0.0042                     
  Solute carrier family 11, member 1                                         5.67                            0.0119                     
  Tumor necrosis factor receptor superfamily, member 1b                      5.65                            0.0007                     
  Interferon regulatory factor 8                                             5.44                            0.0001                     
  Immunity-related GTPase family M member 2                                  5.14           7.03             0.0091                     0.0158
  Bone morphogenetic protein 6                                               5.13                            0.0447                     
  Similar to histocompatibility 2, D region locus 1                          5.06           3.94             0.0053                     0.0238
  Cytochrome b-245, α polypeptide                                            5.03           5.79             0.0211                     0.0092
  Guanylate binding protein 3\*                                              4.99           4.51             0.0107                     0.0010
  Chemokine (C-C motif) ligand 7                                             4.88                            0.0158                     
  Cell division cycle 2 homolog A                                            4.87                            0.0282                     
  SAM domain and HD domain, 1                                                4.81           4.94             0.0045                     0.0064
  B-2 microglobulin mRNA, segment 1                                          4.69                            0.0012                     
  CD40 antigen (Cd40), transcript variant 5                                  4.67                            0.0064                     
  Lymphocyte protein tyrosine kinase                                         4.66           5.74             0.0039                     0.0250
  Fc receptor, IgE, high affinity I, gamma polypeptide                       4.58                            0.0034                     
  Protein tyrosine phosphatase, receptor type, C, transcript variant 2\*     4.54                            0.0046                     
  Immunoglobulin heavy chain complex\*                                       4.46           5.27             0.0058                     0.0043
  SAM and SH3 domain containing 3\*                                          4.45           2.82             0.0123                     0.0054
  Arrestin, β2                                                               4.44                            0.0013                     
  2-5 oligoadenylate synthetase 1B                                           4.39                            0.0160                     
  Fc receptor, IgG, high affinity I                                          4.38           3.21             0.0300                     0.0098
  Protein tyrosine phosphatase, nonreceptor type 22                          4.38                            0.0011                     
  Histocompatibility 2, Q region locus 1                                     4.35           3.11             0.0145                     0.0005
  CD79A antigen                                                              4.3                             0.0022                     
  Leukocyte specific transcript 1                                            4.23                            0.0426                     
  Lymphocyte antigen 86                                                      4.19                            0.0386                     
  2-5 oligoadenylate synthetase-like 2\*                                     4.14           7.25             0.0139                     0.0059
  Myxovirus resistance 1                                                     4.1                             0.0115                     
  Complement component 1, q subcomponent, C chain                            4.04                            0.0011                     
  CD74 antigen                                                               3.98           4.48             0.0119                     0.0003
  CD79B antigen\*                                                            3.95                            0.0497                     
  Toll-like receptor 1                                                       3.95           3.2              0.0138                     0.0130
  Transforming growth factor, β1                                             3.9                             0.0276                     
  SH2 domain protein 1A                                                      3.87                            0.0210                     
  Vav 1 oncogene\*                                                           3.84                            0.0145                     
  B-2 microglobulin, segment 1                                               3.79                            0.0002                     
  Interferon-inducible GTPase-like                                           3.79                            0.0006                     
  Linker for activation of T cells family, member 2\*                        3.68                            0.0308                     
  Interferon induced with helicase C domain 1                                3.59                            0.0162                     
  Complement component 1, q subcomponent, α polypeptide                      3.57                            0.0062                     
  Complement component 3a receptor 1                                         3.57                            0.0025                     
  Interleukin 3                                                              3.55                            0.0146                     
  Histocompatibility 2, class II antigen A, β1                               3.54           3.42             0.0106                     0.0243
  CD3 antigen, epsilon polypeptide                                           3.52                            0.0171                     
  Interleukin 18 receptor 1                                                  3.52                            0.0062                     

Relative ratios were determined from CL and Affy data by comparing the degree of gene expression in lacrimal glands from P- versus T-treated female NOD mice. Listed CL genes were increased ≥3.50-fold.

Genes were found to be down-regulated in lacrimal glands of female MRL/lpr mice treated with T ([Table 7](#i1552-5783-60-6-2181-t07){ref-type="table"}).

Not all immune-related responses to T in the lacrimal glands of female MRL/lpr and NOD mice were opposite. As shown in [Table 9](#i1552-5783-60-6-2181-t09){ref-type="table"}, the expression of certain inflammatory genes was down- or upregulated in the same way in both strains.

###### 

Inflammatory Gene Responses That Were Similar in Lacrimal Glands From Female MRL/lpr and NOD Mice

  **Gene**                                                      **MRL/lpr Ratio**   **NOD Ratio**   **MRL/lpr** ***P*** **Value**   **NOD** ***P*** **Value**
  ------------------------------------------------------------- ------------------- --------------- ------------------------------- ---------------------------
  Downregulation                                                                                                                    
   Indoleamine 2,3-dioxygenase 1                                4.55                3.65            0.0073                          0.0172
   UDP-Gal:βGlcNAc β 1,4-galactosyltransferase, polypeptide 1   4.52                12.98           0.0006                          0.0009
   Interleukin 33                                               2.31                1.84            0.0006                          0.0352
   Tachykinin 1                                                 2.17                2.54            0.0236                          0.0010
   Purinergic receptor P2X, ligand-gated ion channel            1.63                1.78            0.0325                          0.0255
   Adiponectin, C1Q and collagen domain containing              1.46                3.58            0.0101                          0.0046
   Junction adhesion molecule 3                                 1.4                 1.77            0.0068                          0.0136
  Upregulation                                                                                                                      
   TLR4 interactor with leucine rich repeats                    30.47               7.29            0.0277                          0.0011
   Adenosine A2b receptor                                       22.87               9.81            0.0053                          0.0145
   Paraneoplastic antigen MA1                                   16.63               2.91            0.0001                          0.0181
   Carbohydrate sulfotransferase 2                              15.49               2.13            0.0012                          0.0130
   Forkhead box P3                                              11.51               10.7            0.0036                          0.0007
   Nucleotide-binding oligomerization domain containing 2       10.82               2.65            0.0134                          0.0004
   Toll-like receptor 9                                         3.45                1.67            0.0125                          0.0170
   Chemokine (C-C motif) receptor 5                             2.25                2.05            0.0045                          0.0078
   V-rel reticuloendotheliosis viral oncogene homolog A         1.66                3.06            0.0091                          0.0033
   Transforming growth factor, β1                               1.47                3.9             0.0043                          0.0276
   Regenerating islet-derived 3α                                1.42                1.43            0.0207                          0.0222

Relative ratios were calculated from CL data by comparing the degree to which gene expression was significantly down- or upregulated by T treatment, relative to that of P, in lacrimal glands of female MRL/lpr and NOD mice.

The modulatory effect of T on immune-related gene expression in the autoimmune mouse lacrimal glands did not reflect an androgen action typically found in lacrimal tissues of a nonautoimmune strain. Indeed, the effect of T on gene ontologies in lacrimal glands of female NOD, compared to female BALB/c, mice showed significant differences. For example, 21 of 22 androgen upregulated biological process ontologies (Affy) in NOD mice (*n* = 479 NOD \> BALB/c ontologies) with the highest *z*-scores (*z* = 6.85 -- 10.59) were all immune-related. In contrast, only two of the 161 biological process gene ontologies expressed to a greater extent in BALB/c versus NOD mice were immune-associated. Instead, the BALB/c biological process ontologies with the highest *z*-scores were translation elongation (*z* = 11.59), translation (*z* = 9.56) and oxidation-reduction (*z* = 6.87). In the same way, some of the top molecular function and cellular component ontologies in T-treated female NOD mice were immune-related antigen binding (*z* = 8.72), chemokine receptor binding (*z* = 4.63), and MHC protein complex (*z* = 6.64), whereas they were structural constituent of ribosome (*z* = 10.94), mitochondrion (*z* = 12.77) and multiple ontologies related to oxidoreductase activities in androgen-treated female BALB/c mice.

T Impact on Immune-Related KEGG Pathways in Lacrimal Glands of Female MRL/lpr and NOD Mice {#s3c}
------------------------------------------------------------------------------------------

T administration led to a significant decrease in the expression of immune-related KEGG pathways in lacrimal glands of female MRL/lpr mice ([Table 10](#i1552-5783-60-6-2181-t10){ref-type="table"}). These included such pathways as chemokine signaling, cytokine-cytokine receptor interaction, and leukocyte transendothelial migration ([Table 9](#i1552-5783-60-6-2181-t09){ref-type="table"}). In contrast, T induced a significant increase in the expression of these KEGG pathways, as well as many more, in lacrimal tissues of female NOD mice ([Table 11](#i1552-5783-60-6-2181-t11){ref-type="table"}).

###### 

Immune KEGG Pathways Downregulated in Lacrimal Glands by T Administration to Female MRL/lpr Mice

  **KEGG Pathway**                          **CL Genes ↓**   **Affy Genes ↓**  **CL** ***z*****-Score**    **Affy** ***z*****-Score**
  ---------------------------------------- ---------------- ------------------ -------------------------- ----------------------------
  Chemokine signaling pathway                     28                           2.92                       
  Cytokine-cytokine receptor interaction          36                           2.79                       
  Toll-like receptor signaling pathway            17                           2.47                       
  B cell receptor signaling pathway               14                           2.4                        
  Leukocyte transendothelial migration            17                19         2.05                                   2.06
  Phagosome                                       22                           2.01                       

Immune-related KEGG pathways that were decreased in T-, as compared to P-, treated female MRL/lpr mice are listed.

###### 

T Upregulation of Immune KEGG Pathways in Lacrimal Glands of Female NOD Mice

  **KEGG Pathway**                               **CL Genes ↑**   **Affy Genes ↑**   **CL** ***z*****-Score**   **Affy** ***z*****-Score**
  ---------------------------------------------- ---------------- ------------------ -------------------------- ----------------------------
  Natural killer cell mediated cytotoxicity      38               17                 8.37                       2.47
  Graft-versus-host disease                      18               12                 7.96                       4.99
  Allograft rejection                            17               10                 7.41                       3.94
  Antigen processing and presentation            23               16                 7.11                       4.83
  Leishmaniasis                                  24                                  7.03                       
  Autoimmune thyroid disease                     17               10                 6.4                        2.99
  Toll-like receptor signaling pathway           26               16                 5.71                       3.07
  Primary immunodeficiency                       13               9                  5.46                       3.87
  Phagosome                                      32               28                 4.97                       4.85
  Cytokine-cytokine receptor interaction         44                                  4.78                       
  Chemokine signaling pathway                    34               26                 4.67                       3.52
  T-cell receptor signaling pathway              24                                  4.54                       
  Systemic lupus erythematosus                   17               14                 4.25                       3.23
  B-cell receptor signaling pathway              18               12                 4.21                       2.77
  Jak-STAT signaling pathway                     26                                  3.66                       
  Intestinal immune network for IgA production   10                                  3.31                       
  Fc gamma R-mediated phagocytosis               16               14                 2.77                       2.85
  Complement and coagulation cascades            14                                  2.76                       
  Leukocyte transendothelial migration           17               17                 2.17                       2.8

Immune-related KEGG pathways that were increased in T-, as compared to P-, treated female NOD mice are listed.

Comparison Between the Influence of Sex and T on Immune-Related Gene Expression in Lacrimal Glands of MRL/lpr and NOD Mice {#s3d}
--------------------------------------------------------------------------------------------------------------------------

Lacrimal glands of female MRL/lpr and male NOD mice, compared to their opposite sexes, contain a significantly greater expression of genes, ontologies, and KEGG pathways related to inflammatory responses, antigen processing, and chemokine signaling.[@i1552-5783-60-6-2181-b30] We hypothesized that many of these immune-related genes, ontologies, and pathways are analogous to those T suppresses in female MRL/lpr, and induces in female NOD mouse lacrimal tissues. To test this hypothesis, we compared the sex and T influence on immune-related gene expression in MRL/lpr and NOD mice. We also compared these findings to genes more highly expressed in inflamed (MRL/lpr female and NOD male) versus noninflamed (MRL/lpr male and NOD female) lacrimal tissues.

As shown in [Tables 12](#i1552-5783-60-6-2181-t12){ref-type="table"} to [14](#i1552-5783-60-6-2181-t14){ref-type="table"}, many immune-related biological process ontologies (e.g., inflammatory response), immune response genes (e.g., *complement component 3*) and chemokine KEGG pathway genes (e.g., *chemokine* \[*C-X-C motif*\] *ligand 9*) that are influenced by sex and T in lacrimal glands of MRL/lpr and NOD mice are identical. Thus, androgen downregulates multiple immune-related genes that are highly expressed in lacrimal tissues of female MRL/lpr mice, and T upregulates the expression of these immune genes, which typically are expressed in NOD males, in female NOD lacrimal tissues. These regulated genes in [Tables 12](#i1552-5783-60-6-2181-t12){ref-type="table"} to [14](#i1552-5783-60-6-2181-t14){ref-type="table"} are the same as those more highly expressed in inflamed compared to noninflamed lacrimal glands.

###### 

Sex and T Influence on Immune-Related Gene Ontologies in Lacrimal Glands of Autoimmune Mice

  Gene Ontology                                  **lpr**   **lpr**   **lpr**   **lpr**   **NOD**   **NOD**   **NOD**   **NOD**   **lpr +NOD**   **lpr +NOD**
  ---------------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- -------------- --------------
  Immune system process                          228       6.26      166       7.27      227       14.62     192       13.29     238            18.47
  Immune response                                133       5.89      90        5.45      152       15.16     127       13.54     161            18.74
  Defense response                               141       6.12      89        4.73      134       11.7      115       10.91     139            14.42
  Regulation of immune system process            119       4.29      79        3.9       128       11.66     111       11.05     130            13.88
  Leukocyte activation                           100       5.51      65        4.58      99        10.89     87        10.52     112            15.01
  Positive regulation of immune system process   85        3.99      55        3.33      102       12.13     86        10.98     103            14.06
  Lymphocyte activation                          84        4.84      55        4.11      83        9.72      72        9.2       97             14.08
  Regulation of immune response                  77        4.38      43        2.31      90        11.75     77        10.88     89             13.18
  Immune effector process                        74        5.38      39        2.56      81        11.65     71        11.16     84             13.89
  Innate immune response                         56        3.15      46        4.75      69        10.11     62        10.06     74             12.72
  Positive regulation of immune response         59        3.72      37        2.82      75        11.48     62        10.1      74             12.76
  T-cell activation                              55        3.53      38        3.46      60        8.74      53        8.5       67             11.75
  Cytokine production                            72        5.12      41        3.03      63        7.94      59        8.52      66             9.93
  Regulation of leukocyte activation             56        4.11      34        2.87      58        8.71      54        9.16      62             11
  Regulation of lymphocyte activation            51        4.12      32        3.13      54        8.81      48        8.63      60             11.65
  Inflammatory response                          71        4.8       39        2.51      58        6.75      51        6.57      58             7.99
  Regulation of cytokine production              62        4.65      33        2.23      54        7.21      51        7.85      58             9.39
  Regulation of defense response                 60        3.79      41        3.6       55        6.95      49        6.9       56             8.4
  Leukocyte proliferation                        47        4.96      31        4.19      43        7.72      38        7.5       55             12.35
  Lymphocyte proliferation                       46        4.95      30        4.08      43        7.93      37        7.41      55             12.62
  Activation of immune response                  41        2.52      30        2.98      55        9.56      44        8.01      54             10.58
  Response to cytokine stimulus                  49        3.34      47        6.4       45        6.21      39        5.89      48             8.08
  Positive regulation of defense response        39        3.14      29        3.61      37        6.02      32        5.68      37             7.03

The number of genes (i.e., non--*z*-score columns) and *z*-scores (*z*) were obtained by analyzing comparative CL microarray data from lacrimal glands from female (F) versus male (M) and P-versus T-treated MRL/lpr (lpr) and NOD mice. The sex-related data originate from one of our recent publications.[@i1552-5783-60-6-2181-b30] The last two columns on the right show results obtained by comparing gene expression in inflamed (Infl) versus noninflamed lacrimal tissues, as described in the Results section. Ontologies were significantly (*P* \< 0.05) up (↑)- or down (↓)-regulated according to the listed sex and hormone treatment.

###### 

Sex and T Effect on the Expression of Immune Response Genes in Lacrimal Glands of Autoimmune Mice

  Gene Ontology                                       **lpr**   **lpr**   **lpr**   **lpr**   **NOD**   **NOD**   **NOD**   **NOD**   **lpr +NOD**   **lpr +NOD**
  --------------------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- -------------- --------------
  Chemokine (C-X-C motif) ligand 9                    4.21      0.0053    2.22      0.0260    15.74     0.0000    10.01     0.0066    5.56           0.0000
  CD79B antigen                                       3.56      0.0001    2.39      0.0154    11.31     0.0002    3.95      0.0497    5.49           0.0018
  SAM and SH3 domain containing 3                     3.34      0.0019    2.42      0.0070    6.26      0.0001    4.45      0.0123    4.03           0.0000
  Linker for activation of T cells family, member 2   2.48      0.0136    4.09      0.0024    6.04      0.0005    3.68      0.0308    3.93           0.0000
  Vav 1 oncogene                                      2.78      0.0008    2.39      0.0314    5.52      0.0000    3.84      0.0145    3.48           0.0000
  Complement component 3                              4.38      0.0050    2.94      0.0015    3.14      0.0050    3.15      0.0109    3.44           0.0000
  C-type lectin domain family 7, member a             3.11      0.0025    2.24      0.0015    5.45      0.0024    2.99      0.0177    3.29           0.0000
  Immunoglobulin heavy chain complex                  5.47      0.0014    2.71      0.0248    8.51      0.0028    4.46      0.0058    3.2            0.0000
  Complement component 4B                             1.52      0.0361    1.98      0.0147    5.38      0.0053    6.05      0.0054    3.12           0.0000
  interleukin 4 receptor, α                           4.35      0.0039    1.73      0.0241    3.91      0.0025    2.68      0.0279    3.06           0.0015
  Chemokine (C-X-C motif) ligand 16                   6.95      0.0116    3.01      0.0003    1.75      0.0142    2.86      0.0175    2.93           0.0000
  Histocompatibility 2, class II antigen A, α         2.64      0.0142    1.69      0.0065    4.22      0.0017    3.13      0.0064    2.87           0.0000
  Toll-like receptor 1                                2.34      0.0083    1.45      0.0456    4.28      0.0094    3.95      0.0138    2.79           0.0000
  Histocompatibility 2, class II antigen E β          2.3       0.0429    1.59      0.0439    4.87      0.0001    3.18      0.0151    2.77           0.0000
  Toll-like receptor 2                                3.31      0.0033    2.02      0.0104    3.04      0.0003    2.65      0.0111    2.71           0.0000
  Immunity-related GTPase family M member 2           2.25      0.0229    1.94      0.0132    3.79      0.0005    5.14      0.0091    2.69           0.0000
  Chemokine (C-C motif) receptor 2                    2.31      0.0063    2.36      0.0024    3.38      0.0028    2.45      0.0050    2.63           0.0000
  Phospholipid scramblase 1                           3.54      0.0323    2.21      0.0070    2.01      0.0002    2.4       0.0140    2.5            0.0001
  Purinergic receptor P2Y, G-protein coupled, 14      2.32      0.0114    1.34      0.0460    3.69      0.0028    3.15      0.0074    2.47           0.0000
  Transmembrane protein 173                           4.54      0.0033    1.31      0.0113    3.07      0.0007    1.85      0.0383    2.34           0.0000
  Complement component 1, s subcomponent              3.55      0.0039    2.58      0.0013    1.73      0.0096    1.4       0.0133    2.18           0.0002
  Interleukin 1β                                      1.64      0.0146    1.57      0.0329    2.72      0.0001    1.69      0.0456    1.89           0.0001

Relative ratios and *P* values were calculated from CL data by comparing the degree of gene expression in lacrimal glands from female versus male, P- versus T-treated, and inflamed versus noninflamed MRL/lpr and NOD mice. The categories, abbreviations, and origin of the sex-related data are described in the legend to [Table 11](#i1552-5783-60-6-2181-t11){ref-type="table"}.

###### 

Sex and T Impact on the Expression of Genes in the Chemokine KEGG Pathway in Lacrimal Glands Of Autoimmune Mice

  Gene Ontology                                           **lpr**   **lpr**   **lpr**   **lpr**   **NOD**   **NOD**   **NOD**   **NOD**   **lpr +NOD**   **lpr +NOD**
  ------------------------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- -------------- --------------
  Chemokine (C-C motif) receptor 1                        3.4       0.0025    2.58      0.0061    6.88      0.0013    6.4       0.0012    5.64           0.0022
  Chemokine (C-X-C motif) ligand 9                        4.21      0.0053    2.22      0.0260    15.74     0.0000    10.01     0.0066    5.56           0.0000
  Chemokine (C-C motif) ligand 19                         5.29      0.0047    2.24      0.0225    5.58      0.0001    3.53      0.0365    3.8            0.0000
  Vav 1 oncogene                                          2.78      0.0008    2.39      0.0314    5.52      0.0000    3.84      0.0145    3.48           0.0000
  Gardner-Rasheed feline sarcoma viral oncogene homolog   1.49      0.0215    1.57      0.0404    9.32      0.0015    4.63      0.0173    3.24           0.0001
  Chemokine (C-X-C motif) ligand 16                       6.95      0.0116    3.01      0.0003    1.75      0.0142    2.86      0.0175    2.93           0.0000
  Chemokine (C-C motif) receptor 2                        2.31      0.0063    2.36      0.0024    3.38      0.0028    2.45      0.0050    2.63           0.0000
  Hemopoietic cell kinase                                 1.55      0.0340    1.51      0.0419    4.74      0.0005    4.74      0.0348    2.56           0.0000
  Chemokine (C-X-C motif) receptor 6                      2.32      0.0226    2.7       0.0129    3.43      0.0056    1.63      0.0500    2.46           0.0000
  Guanine nucleotide binding protein, gamma 10            1.8       0.0022    1.69      0.0063    1.55      0.0279    1.32      0.0479    1.59           0.0001

Relative ratios and *P* values were determined from CL data as explained in the legends to [Tables 11](#i1552-5783-60-6-2181-t11){ref-type="table"} and [12](#i1552-5783-60-6-2181-t12){ref-type="table"}.

Discussion {#s4}
==========

Our results showed that T significantly influences the expression of numerous immune-related genes, ontologies, and KEGG pathways in lacrimal glands of MRL/lpr and NOD mice. These genes are associated with processes, such as lymphocyte activation, leukocyte transendothelial migration, antigen binding, chemokine signaling, cytokine production, cytokine-cytokine receptor interaction, MHC protein complex, and the inflammatory response. The nature of this androgen-induced response depends upon the autoimmune strain and is not duplicated within lacrimal tissues of nonautoimmune BALB/c mice. The majority of immune-related genes regulated by T are of the inflammatory type. Our findings indicated the lacrimal gland microenvironment as a key mediator of androgen effects on immune gene expression and the associated immunopathology.

Our study was prompted by our earlier discovery that androgens, but not estrogens, dramatically suppress the inflammation in lacrimal tissues of the female MRL/lpr and NZB/NZW FI mouse models of SS.[@i1552-5783-60-6-2181-b11][@i1552-5783-60-6-2181-b12][@i1552-5783-60-6-2181-b13]--[@i1552-5783-60-6-2181-b14] We hypothesized that this androgen effect involves an alteration in the expression and/or activity of immune-related genes, because such genes are critically important in innate and adaptive immune responses.[@i1552-5783-60-6-2181-b42] These genes might also have a major role in promoting the multiple immunosuppressive actions of androgens, including those directly on T cells, monocytes, macrophages, neutrophils, and B cell precursors, and indirectly on peripheral B cells.[@i1552-5783-60-6-2181-b43],[@i1552-5783-60-6-2181-b44] These androgen actions lead to regulation of the maturation, proliferation, migration, and/or function of immune cells; synthesis and secretion of antibodies, cytokines, adhesion molecules, and proto-oncogenes; and expression of autoantigens.[@i1552-5783-60-6-2181-b02],[@i1552-5783-60-6-2181-b43],[@i1552-5783-60-6-2181-b44] A result is that androgens are protective in SS, as well as in other autoimmune diseases, such as systemic lupus erythematosus, multiple sclerosis, and rheumatoid arthritis.[@i1552-5783-60-6-2181-b02],[@i1552-5783-60-6-2181-b05],[@i1552-5783-60-6-2181-b06],[@i1552-5783-60-6-2181-b43]

We discovered that testosterone suppresses a wide array of immune-related genes in lacrimal glands of female MRL/lpr mice. The question is whether some of these genes may be intricately involved in helping to mediate testosterone\'s anti-inflammatory action in this tissue. Possible examples abound. For example, the androgen downregulation of *complement 3*, *Cxcl9*, *moesin*, *IL-1β*, and *TLR2* genes may interfere with the early stages of SS disease development and the triggering of an adaptive immune response in the lacrimal gland.[@i1552-5783-60-6-2181-b30],[@i1552-5783-60-6-2181-b45][@i1552-5783-60-6-2181-b46][@i1552-5783-60-6-2181-b47][@i1552-5783-60-6-2181-b48][@i1552-5783-60-6-2181-b49]--[@i1552-5783-60-6-2181-b50] However, if these five genes are important for the androgen-induced downregulation of lacrimal gland inflammation in female MRL/lpr mice, why are these same genes upregulated by androgen treatment in lacrimal tissues of female NOD mice?

Indeed, we found that many of the immune response genes, immune-related biological process ontologies, and chemokine KEGG pathway genes that are influenced by sex and T in lacrimal glands of MRL/lpr and NOD mice are identical. Thus, androgen decreased the expression of multiple immune-related genes in lacrimal tissues of female MRL/lpr mice, and T increased the expression of these immune genes, which are typically expressed in NOD males,[@i1552-5783-60-6-2181-b30] in female NOD lacrimal tissues. We also discovered that many of these regulated genes are the same as those typically highly expressed in inflamed compared to noninflamed lacrimal glands.

Are there specific genes, then, that might be responsible, at least in part, for promoting the anomalous androgen-induced inflammation in NOD lacrimal glands? Possible genes might be those encoding kallikrein 1 and its related peptidases (KLKs) b1, b4, b5, b8, b11, b24, and b26. Testosterone increased the expression of these genes by 8.4- to 216.7-fold amounts in female NOD lacrimal tissues. KLKs constitute a family of serine proteases that are stimulated by androgens in other tissues[@i1552-5783-60-6-2181-b51] and appear to have a significant role in the development and progression of autoimmune diseases.[@i1552-5783-60-6-2181-b52],[@i1552-5783-60-6-2181-b53] KLK protein levels are increased in lacrimal glands in primary SS.[@i1552-5783-60-6-2181-b54],[@i1552-5783-60-6-2181-b55] Further, several KLKs act as autoantigens, and may serve to elicit an autoimmune T-cell response against lacrimal tissue and to cause a decrease in aqueous tear secretion.[@i1552-5783-60-6-2181-b54],[@i1552-5783-60-6-2181-b56][@i1552-5783-60-6-2181-b57]--[@i1552-5783-60-6-2181-b58] However, it is unlikely that KLKs are the keys to understanding androgen-immune effects in NOD mice. The reason is that T also increases by 1.7- to 273-fold the gene expression of KLKs b1, b4, b8, b10, b11, b16, b21, b24, b26, and b27 in lacrimal glands of female MRL/lpr mice, and by 38.8-fold the KLK b24 gene activity in female nonautoimmune BALB/c mice.[@i1552-5783-60-6-2181-b31]

Another gene that might be responsible for increasing the aberrant androgen-induced inflammation in NOD lacrimal glands is *Syk*. This tyrosine kinase is very much involved in signaling pathways in hematopoietic cells, and also functions within epithelial cells to promote inflammatory responses.[@i1552-5783-60-6-2181-b59],[@i1552-5783-60-6-2181-b60] *Syk* inhibition has been proposed as a potential treatment for SLE and SS.[@i1552-5783-60-6-2181-b61] However, although *Syk* gene expression is increased in the inflamed lacrimal glands of female MRL/lpr mice (NCBI GEO series accession number GSE5876), it is not decreased by androgen treatment in this strain. Consequently, if there is a specific lacrimal gland switch that androgens turn on to induce immunopathology in NOD mice, and turn off to suppress inflammation in MRL/lpr mice, then *Syk* is not that switch.

What, then, is that possible on/off switch? We hypothesized that this switch, which may comprise a single or multiple genes, is triggered by an androgen--androgen receptor interaction within lacrimal gland epithelial cell nuclei. These classical androgen receptors are members of the nuclear receptor superfamily of ligand-inducible transcription factors and mediate the majority of androgen actions throughout the body.[@i1552-5783-60-6-2181-b62],[@i1552-5783-60-6-2181-b63] Following androgen association with its specific receptor, the monomeric, activated androgen-receptor complex binds to androgen response elements in the regulatory region of target genes and, in combination with coactivators and enhancers, regulates gene transcription, and ultimately protein synthesis and tissue function.[@i1552-5783-60-6-2181-b62][@i1552-5783-60-6-2181-b63][@i1552-5783-60-6-2181-b64][@i1552-5783-60-6-2181-b65][@i1552-5783-60-6-2181-b66]--[@i1552-5783-60-6-2181-b67]

We have shown that androgen receptors are located almost exclusively within acinar and ductal epithelial cell nuclei in lacrimal glands of MRL/lpr mice, and are absent within the extensive lymphocytic populations in these autoimmune tissues.[@i1552-5783-60-6-2181-b68] Moreover, we have found that androgens upregulate the expression of androgen receptor protein in MLR/lpr lacrimal gland epithelia, and this autoregulation is particularly intense in ductal epithelial cells.[@i1552-5783-60-6-2181-b68] Indeed, the highest level of androgen receptor protein in ductal nuclei[@i1552-5783-60-6-2181-b68] is elicited by those androgens that possess the greatest anti-inflammatory activity in MRL/lpr lacrimal tissue.[@i1552-5783-60-6-2181-b14] Given the role of the periductal area in promoting inflammation within the lacrimal gland,[@i1552-5783-60-6-2181-b69] it may be that an androgen-controlled on/off switch exists in ductal epithelial cells. Epithelial cells, in turn, are thought to be the primary cells involved in the initiation and perpetuation of glandular autoimmune reactivity in Sjögren syndrome.[@i1552-5783-60-6-2181-b70],[@i1552-5783-60-6-2181-b71]

Consistent with a regulatory role for ductal epithelial cells is the finding that infiltration of lacrimal glands in *AIRE*-deficient NOD mice appears to localize to ductal tissue.[@i1552-5783-60-6-2181-b72] AIRE is a transcription factor and autoimmune regulator that enforces self-tolerance; humans expressing a defective form of this gene develop multiorgan autoimmune disease.[@i1552-5783-60-6-2181-b73] Interestingly, correction of ductal epithelial function also has been shown to correct acinar epithelial function.[@i1552-5783-60-6-2181-b74] This domino effect suggests that ductal cells have an essential role in the pathogenesis of lacrimal gland dysfunction and ultimately aqueous tear film deficiency

Why then is there an aberrant androgen immune response in lacrimal glands of NOD mice? Could this response be related to a genetic alteration in the androgen receptor, or to changes in the hypothalamic-pituitary-adrenal (HPA) axis, or to the diabetes that is characteristic of this strain? Defects in sex steroid receptors have been linked to the onset, progression, and severity, as well as the sex-related prevalence, of a number of autoimmune disorders, including lupus, rheumatoid arthritis, and diabetes.[@i1552-5783-60-6-2181-b75] These defects often are due to gene polymorphisms or alternative splicing and may lead to marked changes in the affinity or specificity of ligand binding, nuclear translocation, receptor dimerization, DNA association, and transcriptional activation.[@i1552-5783-60-6-2181-b75] However, we found that the coding region of androgen receptors in lacrimal glands of NOD and MRL/lpr mice is not defective, but rather normal.[@i1552-5783-60-6-2181-b75] As concerns the HPA axis, we previously discovered that hypophysectomy or anterior pituitary ablation significantly interferes with androgen action on the lacrimal gland.[@i1552-5783-60-6-2181-b76] This lacrimal gland impairment appears to be tissue-specific.[@i1552-5783-60-6-2181-b77] However, although the pituitary has blunted responses in humans with SS,[@i1552-5783-60-6-2181-b78] NOD mice have a hyperactive HPA[@i1552-5783-60-6-2181-b79] and this would not inhibit androgen effects on lacrimal tissue. With regard to diabetes, insulin deficiency is known to attenuate the lacrimal gland response to androgen,[@i1552-5783-60-6-2181-b80] but there is no evidence that this condition would promote a completely opposite immune response to androgens as found in NOD compared to MRL/lpr mice.

As one additional consideration, it has been proposed that a defect in male-specific, lacrimal gland-protective T regulatory cells is the cause of the lacrimal gland inflammation in NOD mice, and is driven by a T regulatory cell-extrinsic factor.[@i1552-5783-60-6-2181-b81] However, given that we were able to induce a striking increase in inflammatory gene expression in lacrimal tissue of NOD female mice, it would seem that androgen action has the key role in this T-cell effector/regulator imbalance.

The androgen-induced up- and downregulation of inflammatory gene expression in NOD and MRL/lpr mice, respectively, appears to be mediated through the lacrimal gland environment. Consistent with this hypothesis are the results of adoptive transfer experiments in NOD mice with severe combined immune deficiency (SCID). These animals lack functional T and B cells and do not suffer autoimmune disease. Transfer of splenocytes or cervical lymph node cells from a female NOD mouse to a male NOD.SCID causes massive inflammatory lesions in the lacrimal gland, whereas transfer of male NOD splenocytes or cervical lymph node cells to a female NOD.SCID does not elicit such lacrimal tissue infiltration.[@i1552-5783-60-6-2181-b24],[@i1552-5783-60-6-2181-b81] Further, the lacrimal gland inflammatory response can be reduced by castration of a male NOD mouse,[@i1552-5783-60-6-2181-b23] and induced by androgen treatment of a female NOD mouse (this study).

It is possible that intracrine steroidogenic enzymes convert androgens in the NOD lacrimal gland into metabolites that act through different mechanisms than testosterone, such as may occur in the brain.[@i1552-5783-60-6-2181-b82] Such byproducts could have aberrant forms, given that unusual androgen metabolites are the key serum biomarkers for dry eye disease.[@i1552-5783-60-6-2181-b83] Alternatively, it is possible that epithelial cells in NOD lacrimal tissue, like human prostate epithelial cells, demonstrate significant plasticity in response to androgens.[@i1552-5783-60-6-2181-b84] Nevertheless, the identity of the microenvironmental switch(es) that translate androgen action into an up- or downregulation of immune-related gene expression in the lacrimal gland remains to be discovered.
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